Hope Medical Enterprise; Inc. d.b.a. Hope Pharmaceuticals
发明人:
Sherman, Craig,Lepine, Anthony James,Smith, Catherine Marie,Wirtz, Kevin Robert,Schulze, Erich
申请号：
AU2015202300
公开号：
AU2015202300B2
申请日:
2015.05.01
申请国别(地区):
AU
年份:
2016
代理人:
摘要：
#$%^&*AU2015202300B220160526.pdf#####ABSTRACT A method of treating a condition associated with elevated blood pressure comprising Administering to a subject a therapeutically effective amount of a purified sodium nitrite which contains no greater than about 0.02% by weight of sodium carbonate or no greater than about 10 ppm of an anti-caking agent； wherein the purified sodium nitrite has a loss on drying of no greater than about 0.25% by weight； wherein the water content in the purified sodium nitrite is no greater than about 0.5% by weight； wherein the purified sodium nitrite contains no greater than about 0.4% by weight of sodium nitrate, and/or no greater than about 0.005% by weight of insoluble matter, and/or no greater than about 0.005% by weight of chloride, and/or no greater than about 0.01% by weight of sulfate, and/or no greater than about 0.001% by weight of iron, and/or no greater than about 0.01% by weight of calcium, and/or no greater than about 0.005% by weight of potassium, and/or no greater than about 0.05 ppm of mercury, and/or no greater than about 2 ppm of aluminum, and/or no greater than about 3 ppm of arsenic, and/or no greater than about 0.003% by weight of selenium； wherein the purified sodium nitrite contains no greater than 5000 ppm of organic volatile impurities； wherein the total non-volatile organic carbon content in the purified sodium nitrite is no greater than about 50 ppm； and wherein the purified sodium nitrite has total aerobic count of microbial load of no greater than about 100 CFU/g, and/or has total yeast and mold count of no greater than about 20 CFU/g, and/or contains no greater than about 0.25 EU/mg of bacterial endotoxins.
